LLY

Eli Lilly & Co
D

LLY

Arincen80/100B

Eli Lilly & Co operating income 1985–2026

Eli Lilly & Co's operating income in Q3 FY2026, the three months to 30 September 2026, was 8.61B USD, up 2.6% on the same quarter a year before. Eli Lilly & Co's operating income over the last twelve months was 39.83B USD, up 50.9% on the twelve months before. In fiscal year 2025 it was 29.70B USD, up 74.3% on the year before.

Last updated 10 Nov 2026 · Next report 3 Feb 2027

Operating income

Operating income · +23.5% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 202639.83B+50.92%46.07%72.31B83.63%44.75B
FY202531 Dec 202529.70B+74.27%45.56%54.13B83.04%31.69B
FY202431 Dec 202417.04B+57.96%37.83%36.63B81.31%18.81B
FY202331 Dec 202310.79B+24.66%31.61%27.04B79.25%8.57B
FY202231 Dec 20228.65B+9.08%30.32%21.91B76.77%8.66B
FY202131 Dec 20217.93B+10.02%28.01%21.01B74.18%8.04B
FY202031 Dec 20207.21B+20.19%29.38%19.06B77.66%8.91B
FY201931 Dec 20196.00B-0.44%26.88%17.60B78.85%6.90B
FY201831 Dec 20186.03B+41.79%28.04%16.81B78.22%5.53B
FY201731 Dec 20174.25B+9.78%21.28%15.53B77.73%4.10B
FY201631 Dec 20163.87B+7.77%18.24%15.51B73.09%5.06B
FY201531 Dec 20153.59B+7.91%18.00%14.92B74.76%4.38B
FY201431 Dec 20143.33B-40.00%16.97%14.68B74.85%4.53B
FY201331 Dec 20135.55B+10.62%24.00%18.21B78.76%7.50B
FY201231 Dec 20125.02B-20.62%22.19%17.81B78.78%7.05B
FY201131 Dec 20116.32B-6.71%26.01%19.22B79.13%6.91B
FY201031 Dec 20106.77B+6.31%29.35%18.71B81.08%8.04B
FY200931 Dec 20096.37B+15.23%29.17%17.59B80.55%6.92B
FY200831 Dec 20085.53B+15.10%27.13%16.00B78.52%43.30M
FY200731 Dec 20074.80B+16.42%25.78%14.38B77.20%5.85B
FY200631 Dec 20064.13B+13.07%26.29%12.14B77.40%4.93B
FY200531 Dec 20053.65B-0.28%24.91%11.17B76.28%4.38B
FY200431 Dec 20043.66B+4.48%26.40%10.63B76.74%4.26B
FY200331 Dec 20033.50B+5.23%27.83%9.91B78.74%4.05B
FY200231 Dec 20023.33B-10.78%30.04%8.90B80.35%3.82B
FY200131 Dec 20013.73B+4.78%32.31%9.38B81.28%4.18B
FY200031 Dec 20003.56B+5.83%32.77%9.24B85.09%4.00B
FY199931 Dec 19993.36B+19.09%33.63%8.34B83.42%3.80B
FY199831 Dec 19982.82B+15.83%30.58%7.71B83.49%3.31B
FY199731 Dec 19972.44B+19.28%30.53%6.55B82.02%2.95B
FY199631 Dec 19962.04B+3.15%29.21%5.67B81.02%2.59B
FY199531 Dec 19951.98B+10.41%29.30%5.43B80.31%2.54B
FY199431 Dec 19941.79B+175.04%31.43%4.46B78.16%2.23B
FY199331 Dec 1993652.60M-43.52%10.11%4.89B75.81%1.05B
FY199231 Dec 19921.16B-34.65%18.74%4.64B75.21%1.52B
FY199131 Dec 19911.77B+14.87%30.88%4.37B76.34%2.07B
FY199031 Dec 19901.54B+32.16%29.65%3.92B75.43%1.79B
FY198931 Dec 19891.16B+11.27%27.90%3.15B75.42%1.39B
FY198831 Dec 19881.05B+75.93%25.72%2.94B72.17%1.25B
FY198731 Dec 1987595.00M-30.84%16.33%2.53B69.30%779.30M
FY198631 Dec 1986860.30M+12.55%23.12%2.55B68.59%1.04B
FY198531 Dec 1985764.40M—23.37%2.23B68.23%900.60M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Eli Lilly & Co's operating income

Source: Financial Modeling Prep